



**PRESS RELEASE  
FOR IMMEDIATE DISCLOSURE**

## **ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS**

Montreal, QC, July 22, 2022 – [Ortho Regenerative Technologies Inc.](#) (CSE: ORTH, OTCQB: ORTIF) ("**Ortho**" or the "**Company**"), a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held via videoconference on July 21, 2022.

### **Election of Directors**

The following seven (7) nominees were elected as Directors of the Company to hold office until the next Annual Meeting of Shareholders or until their successors are elected or appointed:

- Mr. Steve Saviuk
- Dr. Brent Norton
- Mr. Pierre Laurin
- Mr. Patrick O'Donnell
- Mr. Tim Cunningham
- Mr. Howard P. Walthall
- Mr. Philippe Deschamps

### **Appointment of Auditors**

Ernst & Young LLP was appointed as auditor of the Company to hold office until the next Annual Meeting of Shareholders, and the Board of Directors was authorized to fix the auditor's remuneration.

### **Special Resolution authorizing the Amendment of the Articles of Incorporation to Change the Name of the Corporation**

The special resolution authorizing the amendment of the articles of incorporation to change the name of the corporation, as more particularly described in the Circular, was approved.

## **Equity Incentive Plan**

The amendment of the Equity Incentive Plan from a rolling 5% plan to a fixed 10% plan, as more particularly described in the Circular, was approved by a majority of votes from Disinterested Shareholders.

## **Share Option Plan**

The existing 10% rolling share option plan of the Corporation was re-approved for the ensuing year.

## **About Ortho Regenerative Technologies Inc.**

Ortho is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Our proprietary RESTORE technology platform is a proprietary muco-adhesive Chitosan-based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. ORTHO-R, our lead Chitosan-PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. The proprietary Chitosan-PRP combination ORTHO-R implant can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant potential of our technology platform, Ortho continues to assess new therapeutic target uses outside of the soft tissue repair field. Further information about Ortho is available on the Company's website at [www.orthorti.com](http://www.orthorti.com) and on SEDAR at [www.sedar.com](http://www.sedar.com). Also follow us on LinkedIn and Twitter.

## **Forward-Looking Statements**

This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

## **Contacts**

### Company

Philippe Deschamps,  
President and Chief Executive Officer,  
614-596-2597

[deschamps@orthorti.com](mailto:deschamps@orthorti.com)

or

### Investors

Frederic Dumais  
Director Communications and Investor Relations  
(514) 782-8803

[dumais@orthorti.com](mailto:dumais@orthorti.com)